Agenus to Present at OneMedForum San Francisco 2014
January 08 2014 - 4:45PM
Business Wire
Agenus Inc. (Nasdaq: AGEN), a developer of therapeutic vaccines
for cancer and infectious diseases, today announced that the
company will be presenting at the 7th Annual OneMedForum San
Francisco 2014, which will be held at the Westin San Francisco
Market Street in San Francisco. The presentation will take place on
Monday, January 13th at 2:45pm PST.
Web Cast Information
The live and archived webcast of the company presentation will
be accessible from the company’s website at
www.agenusbio.com/webcast. Please log in approximately 5-10 minutes
before each event to ensure a timely connection. The archived
replay will be available on the Agenus website for one month
following the conference.
About Agenus
Agenus Inc. is a biotechnology company developing treatments for
cancers and infectious diseases. The company has multiple
immunotherapeutic products based on strong technology platforms
that are advancing through the clinic. Agenus’ technology is
further validated through partnerships with major pharmaceutical
companies, with several product candidates in late-stage clinical
trials with corporate partners. Between Agenus and its partners, 23
programs are in clinical development. For more information, please
visit www.agenusbio.com, or connect with the company on Facebook,
LinkedIn, Twitter and Google+. For more information, please visit
www.agenusbio.com.
Forward-Looking Statement
This press release contains forward-looking statements,
including statements regarding clinical trial activities, the
publication of data, and the potential application of the Company’s
technologies and product candidates in the prevention and treatment
of diseases. These forward-looking statements are subject to risks
and uncertainties that could cause actual results to differ
materially. These risks and uncertainties include, among others,
the factors described under the Risk Factors section of our
Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission for the period ended September 30, 2013. Agenus
cautions investors not to place considerable reliance on the
forward-looking statements contained in this release. These
statements speak only as of the date of this document, and Agenus
undertakes no obligation to update or revise the statements. All
forward-looking statements are expressly qualified in their
entirety by this cautionary statement. Agenus’ business is subject
to substantial risks and uncertainties, including those identified
above. When evaluating Agenus’ business and securities, investors
should give careful consideration to these risks and
uncertainties.
Media and Investor Contact:Agenus Inc.Jonae R. Barnes,
617-818-2985Vice PresidentInvestor Relations andCorporate
Communicationsjonae.barnes@agenusbio.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Sep 2024 to Oct 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Oct 2023 to Oct 2024